NCT07382505Not yet recruiting
Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer
Prospective Cohort to Evaluate the Prognostic and Early-Recurrence Detection Performance of Blood-based Minimal Residual Disease (MRD) Testing in Endometrial and Cervical Cancer
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
This study aims to evaluate the clinical performance of blood-based Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) in patients with endometrial and cervical cancer. The researchers will investigate whether MRD detection can identify cancer recurrence earlier than current standard imaging or clinical methods (providing a "lead time"). Participants will undergo blood collection at specific time points, including at diagnosis, after surgery, and during regular follow-up visits. The study will also assess the correlation between MRD status and survival outcomes, such as Relapse-Free Survival (RFS) and Overall Survival (OS). The goal is to establish a foundation for personalized treatment strategies based on molecular monitoring.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 27 Jan 2026
- Start date
- 15 Feb 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Asan Medical Center
- NCT number
- NCT07382505
What you commit to
- Study type: Observational
- Planned participants: 600
- From 15 Feb 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Synchronous other malignancies (cancer requiring treatment within the last 5 years).
- Persistent infection or bleeding tendency that makes repeated blood collection unsafe.
- Any condition that the principal investigator deems inappropriate for the study.
Other
- Inability to follow-up or communicate (e.g., due to geographic or cognitive reasons).
Who the study is looking for
- Histologically confirmed endometrial cancer or cervical cancer.
- Scheduled for or completed standard treatment (Surgery, Adjuvant therapy, or CCRT).
- Provision of written informed consent for study participation and biospecimen collection
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Asan Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.